Burlington, Ontario, March 29, 2024–(BUSINESS WIRE)–Anaergia Inc. (“asthenia” or “company“) (TSX:ANRG) today filed its annual information form for the year ended December 31, 2023, audited annual consolidated financial statements for the year ended December 31, 2023, and related Announced that management consultation will be delayed. CEO and CFO certifications related to analysis of financial condition and results of operations and audited annual financial statements as required by National Instrument 52-109 – Certification of disclosures in the issuer's annual and interim returns (collectively referred to as “”Required documents“) If the April 1, 2024 submission deadline has passed.
Due to delays in the financial reporting process due to the accounting and financial reporting implications of the company's restructuring activities and transformation during fiscal year 2023, the audit of Anagya will take additional time. The Company is working diligently to facilitate the completion of Deloitte LLP's audit of its annual consolidated financial statements and expects to be able to file the required documents on or about April 15, 2024.
We expect the OSC to impose a failure to file cease-and-desist order (“CTO“) Compliant with National Policy 11-207 – Non-filing Cease and Desist Orders and Revocations in Multiple Jurisdictions. The CTO shall prohibit any person from trading in our securities in Canada, including trading in our common stock through the Toronto Stock Exchange. Once issued, the CTO remains in place until the necessary documentation is completed by the company.
Anergia shall satisfy the provisions of the Alternative Information Guidelines under NP 12-203 by issuing a biweekly default status report in the form of a news release, as appropriate, unless the above filing requirements are met. . Anagia confirms that there are no bankruptcy proceedings against it and no other material information regarding its operations that is not publicly disclosed. In addition to those disclosed herein, Anaergia has updated its filing obligations.
About analgesia
Anasia was created to eliminate a major source of greenhouse gases (“greenhouse gas“) by cost-effectively converting organic waste into renewable natural gas (“NGWith a track record of delivering innovative projects, Anaergia is uniquely positioned to deliver solutions to today's most pressing resource recovery challenges using a broad portfolio of proven technologies and multiple project delivery methods. there is. has a unique portfolio of end-to-end solutions that integrate solid waste and wastewater treatment with organic recovery, high efficiency anaerobic digestion, RNG production, and fertilizer and water recovery from organic residues. One of the only companies in the world. Together, these technologies will enhance the production of carbon-negative biogas, clean water, and natural fertilizers, minimize the footprint, and reduce waste and wastewater treatment costs and GHG emissions.
For more information, please visit www.anaergia.com.
Forward-looking statements
This news release contains forward-looking information within the meaning of applicable securities laws and concerns future events, including, without limitation, statements regarding the expected filing dates of required documents and the imposition of a CTO. reflects current expectations. Forward-looking information is subject to a number of assumptions, including, but not limited to, the Company's ability to file required documentation by April 15, 2024 and the Company's ability to continue to meet its financing and liquidity requirements. Based on. We are subject to numerous risks and uncertainties, many of which are beyond our control. Such risks and uncertainties include, but are not limited to, the risk that the filing of required documentation will be delayed longer than expected; the risk that trading in our securities will be suspended by the Toronto Stock Exchange; and/or the risk that trading will be suspended; Not limited to these. After the April 1, 2024 filing deadline, the filing of required documentation, counterparty risk exposure, and the factors discussed under “Risk Factors” in the Company's Annual Information Form for the year ended December 31, Until filed, it is provisionally filed by the Canadian Securities Commission. 2022 and beyond under “Risks and Uncertainties” in our most recent management discussion and analysis. Actual results may differ materially from those projected here. Anergia undertakes no obligation to update such forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities laws. Additional information regarding these and other factors that may affect Anergia's operations and financial results is contained in Anergia's reports filed with Canadian regulatory authorities.
View source version on businesswire.com. https://www.businesswire.com/news/home/20240328101830/ja/
contact address
For media and/or investor relations, please contact IR@Anaergia.com.
